Financials data is unavailable for this security.
View more
Year on year Essex Bio-Technology Ltd grew net income 22.11% from 225.41m to 275.26m primarily through revenue growth (1.32bn to 1.71bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 29.51% growth in revenues contributed enough to still see net income improve.
| Gross margin | 89.78% |
|---|---|
| Net profit margin | 16.24% |
| Operating margin | 21.42% |
| Return on assets | 9.07% |
|---|---|
| Return on equity | 13.75% |
| Return on investment | 12.10% |
More ▼
Cash flow in HKDView more
In 2023, cash reserves at Essex Bio-Technology Ltd fell by 33.64m. However, the company earned 339.21m from its operations for a Cash Flow Margin of 19.88%. In addition the company used 54.34m on investing activities and also paid 309.92m in financing cash flows.
| Cash flow per share | 0.535 |
|---|---|
| Price/Cash flow per share | 4.04 |
| Book value per share | 3.55 |
|---|---|
| Tangible book value per share | 1.59 |
More ▼
Balance sheet in HKDView more
| Current ratio | 1.68 |
|---|---|
| Quick ratio | 1.61 |
| Total debt/total equity | 0.1624 |
|---|---|
| Total debt/total capital | 0.1397 |
More ▼
Growth rates in HKD
SmartText is unavailable
| Div yield(5 year avg) | 1.92% |
|---|---|
| Div growth rate (5 year) | 7.39% |
| Payout ratio (TTM) | 19.47% |
| EPS growth(5 years) | 3.53 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 3.32 |
More ▼
